Abstract:Psoriasis is a persistent, inflammatory condition affecting millions globally, marked by excessive keratinocyte proliferation, immune cell infiltration, and widespread inflammation. Over the years, therapeutic approaches have developed significantly, shifting from conventional topical treatments and phototherapy to more sophisticated systemic interventions such as biologics and, recently, oral small-molecule drugs. This review seeks to present a comprehensive investigation of the existing psoriasis treatment options, focusing on biologic agents, oral small molecules, and emerging treatments. Several categories of biologic treatments have received regulatory approval for psoriasis, including TNF-α, IL-17, IL-12/23, and IL-23 inhibitors. Biologics have revolutionized the treatment of psoriasis. These targeted therapies offer significant improvement in disease control and quality of life, with acceptable safety profiles. However, limitations such as cost, potential immunogenicity, and administration challenges have driven the exploration of alternative treatment modalities. Oral small molecules, particularly inhibitors of Janus kinase (JAK), have emerged as options due to their convenience and efficacy. These agents represent a paradigm shift in the management of the condition, offering oral administration and targeted action on specific signaling pathways. In addition to existing therapies, the review explores emerging treatments that hold promise for the future of psoriasis care. These include innovative small-molecule inhibitors. Early-stage clinical trials suggest these agents may enhance outcomes for psoriasis patients. In conclusion, the therapeutic landscape of psoriasis is rapidly evolving, emphasizing targeted, patient-centered treatments. Ongoing research and development are expected to lead to more personalized and effective management strategies for this complex condition.

Small-molecule inhibitors of protein kinase C, the Janus kinases (JAK) pathway and phosphodiesterases in the treatment of psoriasis

Small Molecule Approaches to Treat Autoimmune and Inflammatory Diseases (part I): Kinase Inhibitors.

Targeting VEGF/VEGFR in the Treatment of Psoriasis.

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

Small Molecules in the Management of Psoriasis and Psoriatic Arthritis

Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature

Novel Biologics in Treatment of Psoriatic Arthritis

Discovery of Janus Kinase and Histone Deacetylase Dual Inhibitors as a New Strategy to Treat Psoriasis

Systemic Treatment of Psoriasis with JAK Inhibitors: A Review

Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules

52574 Safety and Efficacy of Selective TYK2/JAK1 Inhibitor, TLL-018, in Moderate-to-severe Plaque Psoriasis

Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway

Molecular treatment trajectories within psoriatic T lymphocytes: a mini review

Natural Modulators Of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation

New Treatment Addressing the Pathogenesis of Psoriasis

A Novel Treatment for Psoriatic Arthritis: Janus Kinase Inhibitors

[Janus kinase inhibitors for skin disorders]

Newly discovered biologic agent used for psoriasis treatment

Advances in psoriasis research: From pathogenesis to therapeutics

New and emerging oral therapies for psoriasis

ULK1 Inhibition as a Targeted Therapeutic Strategy for Psoriasis by Regulating Keratinocytes and Their Crosstalk With Neutrophils